WhiteOak Capital Mid Cap Fund
The Scheme is to seek to generate capital appreciation by actively investing in and managing a diversified portfolio primarily composed of mid-cap stocks.
Growthvine rating: 5/5 — ranked #3 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹20.99 (as of 2026-10-01) |
|---|
| AUM | ₹6,792 Cr |
|---|
| Expense ratio | 1.54% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Piyush Baranwal |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Sharpe ratio | 0.92 |
|---|
| Standard deviation | 16.88% |
|---|
| Max drawdown | −19.68% |
|---|
| Alpha | 4.07 |
|---|
| Beta | 0.91 |
|---|
Over 5 years, captured 101.9% of NIFTY Midcap 150's upside and 88.9% of its downside.
Market cap allocation
| Large cap | 5.5% |
|---|
| Mid cap | 70.0% |
|---|
| Small cap | 24.4% |
|---|
Concentration
| Top 5 holdings | 14.0% |
|---|
| Top 10 holdings | 23.7% |
|---|
| Total holdings | 133 |
|---|
| Index overlap | 38.2% |
|---|
| Active share | 61.8% |
|---|
Top holdings
- Clearing Corporation of India Ltd — 5.3%
- Max Financial Services Limited — 3.1%
- COFORGE LIMITED — 2.9%
- Bharti Hexacom Limited — 2.7%
- Federal Bank Ltd. — 2.7%
- PB Fintech Limited — 2.6%
- Laurus Labs Limited — 2.0%
- Vishal Mega Mart Limited — 1.9%
- The Phoenix Mills Ltd. — 1.9%
- Motilal Oswal Financial Services Limited — 1.9%
Top sectors
- Banking & Financial — 12.1%
- Retail — 11.6%
- Pharma & Biotech — 10.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 4.6% | Q1 (Top) | #5 of 31 |
| 2025 | 5.2% | Q1 (Top) | #6 of 29 |
| 2024 | 33.4% | Q1 (Top) | #7 of 29 |
| 2023 | 41.5% | Q1 (Top) | #6 of 28 |